Pemazyre is a cancer medicine used to treat adults with cholangiocarcinoma (biliary tract cancer or cancer of the bile ducts) when the cancer cells have an abnormal form of a receptor (target) called FGFR2 on their surface. Pemazyre is used when the cancer has spread to other parts of the body or cannot be removed by surgery and has worsened after previous treatment with at least one cancer medicine. Cholangiocarcinoma is rare, and Pemazyre was [designated an ‘orphan medicine’](/en/medicines/human/orphan-designations/eu-3-18-2066) (a medicine used in rare diseases) on 24 August 2018. Pemazyre contains the active substance pemigatinib.
Therapeutic Indication
### Therapeutic indication Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
Therapeutic Area (MeSH)
ATC Code
L01EN02
ATC Item
pemigatinib
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| pemigatinib | N/A | 佩米替尼 |
EMA Name
Pemazyre
Medicine Name
Pemazyre
Aliases
N/ANo risk management plan link.
